Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study

Danese, S; Rudzinski, J; Brandt, W; Dupas, Jl; Peyrin-Biroulet, L; Bouhnik, Y; Kleczkowski, D; Uebel, P; Lukas, M; Knutsson, M; Erlandsson, F; Hansen, Mb; Keshav, S